The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
58th ERA-EDTA Congress - Fully Virtual 2021 Industry Sponsored by Bayer June 5-8, 2021
Presentations of the Bayer Industry Symposium at the ERA-EDTA
Thank you for your interest! Please see below to download PDFs of the presentation of the Bayer Industry Symposia at ERA-EDTA Fully Virtual Congress 2021.
Access to the presentations will be available after the virtual congress presentation including a full reference list at the end of the page.
Finerenone
Sunday 6 June, 2021 | 13:35 - 13:45 CEST
Nonsteroidal MRAs to improve outcomes in patients with CKD and T2D
Inflammation and fibrosis: An overlooked driver of CKD progression in TD2?
Presentation: TBC
Sunday 6 June, 2021 | 13:45 - 14:00 CEST
Nonsteroidal MRAs to improve outcomes in patients with CKD and T2D
The FIDELIO-DKD trial: New insights on the benefits of MR antagonism
Presentation: TBC
Sunday 6 June, 2021 | 14:00 – 14:15 CEST
Nonsteroidal MRAs to improve outcomes in patients with CKD and T2D
From the trial to the clinic: Applying the evidence to everyday practice
Presentation: TBC
ERA-EDTA: References and further reading
ERA-EDTA: References and further reading
Overview of the latest clinical trials
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
ERA-EDTA: References and further reading
SGLT-2is in CKD
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
ERA-EDTA: References and further reading
GLP-1RAs in CKD and T2D
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
ERA-EDTA: References and further reading
Effects of SGLT-2is on kidney and CV outcomes in CKD
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
ERA-EDTA: References and further reading
The relationship between the MR and CKD in T2D
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
EASD: References and further reading
EASD: References and further reading
Meet the Expert’ session
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
EASD: References and further reading
The MR in CKD in T2D
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
EASD: References and further reading
VERTIS CV outcomes
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
EASD: References and further reading
Overview of the SGLT-2i CVOT trials
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
EASD: References and further reading
SGLT-2is, GLP-1RAs and the cardiorenal metabolic continuum
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
ASN: References and further reading
ASN: References and further reading
ASN session recording
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
ASN: References and further reading
NEJM publication
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
AHA: References and further reading
AHA: References and further reading
Circulation publication
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date accessed: 7 May 2021
Runcaciguat
CKD Epidemiology, Biomarkers, Predictors
Chronic kidney disease by previous diabetes or hypertension: a longitudinal outcomes study in primary care
Presentation: PO0439
View Video of Presentation
Download the Poster
BAY 2327949 (Vasopressin V1a Receptor Antagonist)
CKD Mechanisms - 2
The novel potent and selective vasopressin V1a antagonist BAY 2327949 blocks AVP-mediated decline of renal blood flow and tissue oxygenation
Presentation: PO0647Molidustat
Late-Breaking Clinical Trials Posters
Results from a phase 3 study comparing the efficacy and safety of molidustat vs darbepoetin alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAs)
Presentation: PO2623Strategic Research Collaboration with Vanderbilt University
CKD Mechanisms - 2
Genetic ablation of CD148 increases renal macrophage inflammation and fibrosis in ureteral obstructed kidney
Presentation: PO0654